Roderick Slavcev

Professor, School of Pharmacy

Research interests: novel bacteriophage nanomedicines for the development of novel vaccines; pharmaceuticals and gene delivery systems


Professor Roderick Slavcev specializes in bacteriophage (phage) and molecular biology with experience in both academic and industrial settings. Prior to gathering valuable marketing and clinical experience as a medical liaison for the pharmaceutical industry he completed his post-doctoral fellowship at the Department of Medical Genetics and Microbiology at the University of Toronto in the area of bacteriophage P1 plasmid partition and chromosomal segregation. His current research group comprises Mediphage Bioceuticals (MB) and encompasses phage-based solutions with the ultimate aim of bringing new treatments to the global environment, especially less developed countries. MB research projects focus on the exploitation of bacteriophages and this rich genetic reservoir in the design and construction of synthetic biological production platforms. MB exploits coliphages and phage-encoded genes and genetic elements to design and construct vectors for the development of novel vaccines, targeted gene therapy systems, and the identification and application of novel phage genomic anti-bacterial genes to treat and dispose of the clinical culprits of global bacterial infection.


  • Post-Doctoral Fellow, University of Toronto

  • PhD, Microbial Genetics, University of Saskatchewan

  • MBA, Biotechnology Management and Commercialization, University of Saskatchewan

  • HBSc, University of Toronto

Roderick Slavcev


Research projects in the Slavcev lab focus on the production and characterization of novel bacteriophage (phage)-based nanomedicines and include the use of coliphages and filamentous phages in the design and construction of vectors for the development of novel vaccines, pharmaceuticals and gene delivery systems. Current projects include:

  1. Modulated phage display of bacteriophage Lambda and genomic engineering in the production of a targeted transgene delivery vector.
  2. In vivo production system for highly efficient and safe linear covalently closed DNA “Ministrings” as an optimal transgene delivery vector in nonviral gene delivery
  3. Combination of DNA Ministring technology with modulated phage display targeting in development of new nanomedicines toward treatment of ovarian cancer, HIV and bacterial infection.

Further information on our research can be found at


Dr Slacvec Research

Dr Slacvec Research


Scientific Articles

  • Nafissi, N., Alqawlaq, S., Lee, E., Spagnuolo, P., Foldvari, M. and R.A. Slavcev*. 2014. Ministring DNA: Highly Safe and Effective DNA Transgene Delivery Vectors. Molecular Therapy Nucleic Acids (In Press)

  • Sum, C., Chong, J., Wettig, S. and R.A. Slavcev*. 2014. Purification of Linear Covalently Closed (LCC) DNA Ministrings by Q-Anion Exchange Membrane Chromatography. Chromatography A 1339: 214-218.

  • Nafissi, N., Sum, C., Wettig, S. and R.A. Slavcev* 2014. Optimization of a one-step inducible in vivo mini DNA vector production system. PLOS One 9: e89345.

  • Nicastro, J., Sheldon, K., and R.A. Slavcev*. 2014. Phage Display Applications. Applied Microbiology and Biotechnology98: 2853-66.

  • Nafissi, N., and R.A. Slavcev*. 2014. Bacteriophage recombination systems and biotechnological applications.Applied Microbiology and Biotechnology 98: 2841-51.

  • Nicastro, J., Sheldon, K., El-zarkout, F., Sokolenko, S., Aucoin, M., and R.A. Slavcev*. 2013. Construction and analysis of a genetically tuneable lytic phage display system. Applied Microbiology and Biotechnology 97:7791-7804.

  • Nafissi, N., and R.A. Slavcev*. 2012. Construction and Characterization of an in vivo linear covalently closed DNA vector production system. Microbial Cell Factories 11: 154-167.

  • Sokolenko, S., Nicastro, J., Slavcev, R.A., and M. Aucoin*. 2012. Graphical analysis of flow cytometer data for characterizing controlled fluorescent protein display on λ phage. Cytometry A 81: 1031-1039.

  • Kaur, T., Nafissi, N., Wasfi, O., Sheldon, K., Wettig, S., and R.A. Slavcev*. 2012. Immunocompatibility of Bacteriophages as Nanomedicines. Journal of Nanotechnology, 2012: 1-13.

  • Slavcev, R.A.*, Nafissi, N., and T. Kaur. 2012. SSINCC: Simple Separation of Interacting Nucleoprotein Complex Components. Advances in Biological Chemistry 2: 146-151.

  • R.A. Slavcev*. 2012. The Disparity of Motivational Drivers in International Health Care Systems. Pharmaceutical Regulatory Affairs 1: 1-2.

Education Articles

  • Huang, E. and R.A. Slavcev*. 2013. A Celebration of the Innovation and Entrepreneurship at University of Waterloo 2nd Annual Business Awards Ceremony. Canadian Pharmacists Journal/Revue des Pharmaciens du Canada 146: 251-252.

  • Slavcev, R.A.* Cheung, D., and J. Tjendra. 2013. A needs-driven model for strategic pharmacy education. Currents in Pharmacy Teaching and Learning 5: 593-599.

  • Slavcev, R.A.*, Tjendra, J., Boran, V. and N. Kanji. 2013. Pharmacy Investment Club: Fostering financial management skills from beyond the classroom. Canadian Pharmacists Journal/Revue des Pharmaciens du Canada 146: 144-145.

  • Slavcev, R.A.*, and A. Patel. 2012. Industrial Case Competition: Where Healthcare Interfaces Innovation.CPJ/RPC 145: 251.

  • Tjendra, J., Slavcev, R.A.*, and M. Stanley. 2012. University of Waterloo celebrates innovation and entrepreneurship.Canadian Pharmacists Journal/Revue des Pharmaciens du Canada 145:6-7.


  • Kaur, T., and R.A. Slavcev*. 2013. Solid Lipid Nanoparticles: “Tuneable Anti-Cancer Gene/Drug Delivery Systems”. In:Gene Therapy/Book 1, InTech Open Access Publisher.

Patent Submissions

  • Slavcev, R. and J. Nicastro. 2014. A Fine-tuned Lytic Phage Display System. USPTO serial #: 61/815467 (Under Review)

  • Slavcev, R. and N. Nafissi. 2014. In vivo linear covalently closed DNA vector production system. USPTO serial #: 61/729,384 (Under Review)